Overview

Flu Vaccines Market Dynamics:

Influenza is a contagious respiratory infection that causes cough, runny nose, severe illness. As per the World Health Organization, 2018, over 4 million people were diagnosed with severe illness whereas over 0.1 million influenza-related deaths were registered. Additionally, as per the report published by Center for Disease Control and Prevention in 2019, over 90 pediatric deaths were registered owing to flu. Furthermore, growing research and development activities along with current clinical trials for developing novel flu vaccines shall bolster the flu vaccines market growth.

Moreover, rise in the number of healthcare centers in both developed and developing nations has boosted the proliferation of the market. Additionally, many key players are heavily investing in research and development activities for increasing their manufacturing capabilities and the product spectrum. These vendors are establishing new facilities for enhancing their production capabilities. The demand for flu vaccines has skyrocketed due to the current COVID-19 pandemic and many companies are initiating in producing vaccines for this virus. For example, Bharat Biotech has declared to collaborate with FluGen, a US-based biotech company and the University of Wisconsin Madison for experimenting with flu vaccines that have the potential of fighting off the SARS COV-2 virus. Many players have also reached the levels of advance clinical trials and government bodies are providing financial as well as infrastructural support to these companies.

Flu Vaccines Market Segmentation:

By Product Type
• Trivalent Flu Vaccines
• Quadrivalent Flu Vaccines

By Dosage Form
• Intramuscular Injection
• Nasal Sprays
• Intradermal Shot

By Distribution Channel
• Hospitals
• Community Clinics
• Public Health Agencies
• Workplace Purchasing
• Retail Pharmacy
• Mail Order Pharmacy

By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

The market is categorized into product type, dosage form, distribution channel and region. The product type segment is fragmented into trivalent vaccines and quadrivalent vaccines. The dosage form segment is classified into intradermal shots, intramuscular injection and nasal shots. The distribution channel segment is diversified into hospitals, community clinics, public health agencies, workplace purchasing, retail pharmacy and mail order pharmacy. The hospital segment is anticipated to hold the largest flu vaccines market share owing to a rise in the number of multispecialty hospitals and advancements in the hospital infrastructure.

Regional Analysis:
The North America region is expected to dominate the market and this can be credited to the rising awareness regarding the spread and prevention of flu, growing investments in the research and development of flu vaccines, favorable reimbursement policies and a strong presence of key market players in the region. The Europe region has experienced the growing prevalence of flu in the region which has boosted the market growth in the region.

Competitive Landscape:                            
The major market players associated are Sanofi Pasteur Inc. (Sanofi S/A), AstraZeneca, Abbott, GlaxoSmithKline Plc., Serum Institute of India Pvt. Ltd., CSL Ltd. (Seqirus), Zydus Cadila, Bharat Biotech, Panacea Biotech, Mylan, Sinovac Biotech,Mitsubishi Tanabe Pharma.

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key market trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the global flu vaccines market by product type, by dosage form, by distribution channel and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Flu Vaccines Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Flu Vaccines Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Flu Vaccines Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Flu Vaccines Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Trivalent Vaccines
   7.2. Quadrivalent Vaccines

8. Flu Vaccines Market, By Dosage Form Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Intramuscular Injection
   8.2. Nasal Sprays
   8.3. Intradermal Shots

9. Flu Vaccines Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospitals  
   9.2. Community Clinics
   9.3. Public Health Agencies
   9.4. Workplace Purchasing
   9.5. Retail Pharmacy
   9.6. Mail Order Pharmacy  

10. North America Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Flu Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. Sanofi Pasteur Inc. (Sanofi S/A)
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. AstraZeneca
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Abbott
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. GlaxoSmithKline Plc.
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Serum Institute of India Pvt. Ltd.
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. CSL Ltd. (Seqirus)
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview     
    16.7. Zydus Cadila
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. Bharat Biotech
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Panacea Biotech
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview
    16.10.Mylan
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview
    16.11.Sinovac Biotech
          16.11.1. Company Overview
          16.11.2. Product Portfolio
          16.11.3. SWOT Analysis
          16.11.4. Financial Overview
          16.11.5. Strategic Overview          
    16.12.Mitsubishi Tanabe Pharma
          16.12.1. Company Overview
          16.12.2. Product Portfolio
          16.12.3. SWOT Analysis
          16.12.4. Financial Overview
          16.12.5. Strategic Overview      

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures